ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,142.15
-0.06%
Dow Jones
38,804.39
0.56%
Gold vs US Dollar
2,318.765
-0.61%
Brent Oil
83.905
2.17%
Bitcoin
66,774.77
0.20%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Pardes Biosciences Inc (PRDS)

  7. Pardes Biosciences Inc (PRDS) News

Pardes Biosciences (PRDS)

Pardes Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PRDS
DateTimeSourceHeadlineSymbolCompany
11/09/202313:00Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:PRDSPardes Biosciences Inc
31/08/202322:17Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202319:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRDSPardes Biosciences Inc
31/08/202319:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRDSPardes Biosciences Inc
31/08/202314:06Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PRDSPardes Biosciences Inc
31/08/202314:03Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PRDSPardes Biosciences Inc
31/08/202314:01Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PRDSPardes Biosciences Inc
31/08/202313:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRDSPardes Biosciences Inc
31/08/202313:53Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202313:34Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202313:30Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202313:15GlobeNewswire Inc.Pardes Biosciences Announces Closing of Tender OfferNASDAQ:PRDSPardes Biosciences Inc
28/08/202317:11Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:PRDSPardes Biosciences Inc
28/08/202317:08Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PRDSPardes Biosciences Inc
28/08/202316:52Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:PRDSPardes Biosciences Inc
28/08/202316:33Business WireMediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes BiosciencesNASDAQ:PRDSPardes Biosciences Inc
17/08/202322:43Business WireMediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences SharesNASDAQ:PRDSPardes Biosciences Inc
17/08/202322:11Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:PRDSPardes Biosciences Inc
17/08/202322:09Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PRDSPardes Biosciences Inc
17/08/202321:59Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:PRDSPardes Biosciences Inc
04/08/202321:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRDSPardes Biosciences Inc
04/08/202321:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRDSPardes Biosciences Inc
28/07/202322:08Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:PRDSPardes Biosciences Inc
28/07/202322:04Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:PRDSPardes Biosciences Inc
28/07/202322:01Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:PRDSPardes Biosciences Inc
17/07/202312:58Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:PRDSPardes Biosciences Inc
17/07/202312:55Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:PRDSPardes Biosciences Inc
17/07/202312:11Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:PRDSPardes Biosciences Inc
17/07/202312:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRDSPardes Biosciences Inc
17/07/202312:00GlobeNewswire Inc.Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value RightsNASDAQ:PRDSPardes Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:PRDS

Your Recent History

LSE
EEE
Empire Metals
LSE
BT.A
Bt
LSE
LLOY
Lloyds Banking
LSE
PANR
Pantheon Resources
LSE
VAST
Vast Resources
LSE
ARCM
Arc Minerals
LSE
BIRD
Blackbird
LSE
GKP
Gulf Keystone Petroleum
LSE
SOLG
Solgold
LSE
THG
Thg
LSE
POS
Plexus
LSE
LBE
Longboat Energy
LSE
SDRY
Superdry
LSE
KEFI
Kefi Gold And Copper
LSE
INSG
Insig Ai
LSE
GOLD
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved